COVID-19: Updates on vaccines and therapeutics


Keep on top of the latest updates on therapeutics and vaccines for COVID-19, from new partnerships to clinical trials.

5 June 2020

  • Oxford University (UK) study finds “no clinical benefit” for hydroxychloroquine in hospitalised COVID-19 patients as part of the RECOVERY trial
  • Sorrento Therapeutics (CA, USA) announces promising results from preclinical trials testing its antibody STI4398 (COVIDTRAP), citing its ability to neutralize and inhibit SARS-CoV-2
  • Sun Pharma (Mumbai, India) initiates Phase II clinical trial of AQCH as potential treatment for COVID-19
  • Algernon (Vancouver, Canada) receives FDA clearance for Phase IIb/III clinical trial to evaluate ifenprodil as a potential COVID-19 therapeutic
  • iBio (DE, USA) announces initiation of preclinical immunization studies for its second COVID-19 vaccine platform
  • AbbVie (IL, USA) enters into a collaboration with Harbour BioMed (MA, USA), Utrecht University (Netherlands) and Erasmus Medical Center (Rotterdam, Netherlands) to develop an antibody therapeutic to prevent and treat COVID-19

4 June 2020

  • Intravacc (Bilthoven, Netherlands) partners with Wageningen Bioveterinary Research (Lelystad, Netherlands) and Utrecht University (Netherlands) to develop an intranasal COVID-19 vaccine
  • AstraZeneca (Cambridge, UK) signs agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance and the Serum Institute of India (SII) with a goal to broaden global access to an experimental COVID-19 vaccine being developed at the University of Oxford (UK)
  • INOVIO (PA, USA) and the International Vaccine Institute partner with Seoul National University Hospital (South Korea) to initiate a Phase I/II clinical trial of INOVIO’s COVID-19 DNA vaccine (INO-4800) in South Korea
  • Memo Therapeutics AG (Zurich, Switzerland) identifies potent SARS-CoV-2 neutralizing antibodies from convalescent plasma, with the potential for development as a COVID-19 immunotherapy
  • South Korea’s Ministry of Food and Drug Safety approves the use of Gilead’s (CA, USA) remdesivir to treat COVID-19
  • WHO resumes study of hydroxychloroquine for COVID-19 after safety review

3 June 2020

  • Intravac (Bilthoven, Netherlands) and EpiVax (RI, USA) collaborate to further progress a novel vaccine against COVID-19
  • FDA approves AgenTus’ (Waterloo, Belgium) IND application for an allergenic iNKT therapy for COVID-19
  • London’s Guy’s & St Thomas’ NHS Foundation Trust, King’s College London (UK) and the pharmaceutical organisation the SEEK Group launch the LIBERATE trial, testing a unique formulation of ibuprofen treatment for COVID-19 ARDS
  • Eleva’s (Freiberg, Germany) drug candidate, factor H, is to be examined for use in COVID-19 treatment
  • FSD Pharma (Cobourg, Canada) receives FDA approval for a Phase IIa clinical trial of FSD-201 to treat patients with suspected or confirmed COVID-19

2 June 2020

  • Trevena (PA, USA) announces collaboration with Imperial College London (UK) to evaluate TRV027 in COVID-19 patients
  • First COVID-19 patient dosed with BerBenBio’s (Bergen, Norway) bemcentinib in ACCORD Trial
  • Cellenkos (TX, USA) announces FDA clearance to initiate Phase 1 trial of cryopreserved cord blood-derived T-regulatory cells (CK0802) for treatment of COVID-19 associated ARDS
  • Relief Therapeutics (Geneva, Switzerland) and NeuroRx (DE, USA) announce enrollment of first patients with RLF-100 in Phase IIb/III clinical trial in patients with COVID-19 associated ARDS
  • Resverlogix plans COVID-19 clinical trial program launch testing apabetalone
  • FDA authorizes OPKO Health (FL, USA) clinical trial evaluating RAYALDEE in COVID-19 patients

1 June 2020

  • OPKO Health (FL, USA) announces FDA authorization of Phase II clinical trial evaluating RAYALDEE (calcifediol) extended-release capsules to treat symptomatic patients infected with SARS-CoV-2
  • Tonix Pharmaceuticals (NY, USA) announces partnership with FUJIFILM Diosynth Biotechnologies (NC, USA) to manufacture COVID-19 vaccine candidate TNX-1800
  • Altimmune (MD, USA) announces FDA authorization for clinical trial of T-COVID, an investigational intranasal immune modulator for the treatment of patients with early COVID-19
  • CTI BioPharma (WA, USA) enrols first patient in PRE-VENT Phase III clinical trial of pacritinib in hospitalized patients with severe COVID-19
  • Eli Lilly (IN, USA) doses first patients in a Phase I trial investigating the experimental antibody LY-CoV555 for the treatment of COVID-19
  • Celltrion (Incheon, South Korea) announces positive pre-clinical results for COVID- 19 antiviral antibody treatment, demonstrating a 100-fold reduction in viral load
  • Russian Health Ministry approves Avifavir, its first domestic drug for COVID-19

29 May 2020

  • Atossa Therapeutics (WA, USA) announces second COVID-19 program using its proprietary drug candidate AT-301, to be administered by nasal spray
  • Cincinnati Children’s Hospital (OH, USA) HLH research points to ruxolitinib as a treatment for COVID-19 cytokine storms
  • Indonesia to keep prescribing chloroquine and hydroxychloroquine for COVID-19 despite bans in Europe

28 May 2020

  • PhaseBio (PA, USA) announcs FDA authorization to proceed with a clinical trial termed VANGARD, to evaluate PB1046 as a treatment for hospitalized COVID-19 patients
  • The UK Medicines and Healthcare products Regulatory Agency announces the international COPCOV trial of hydroxychloroquine, led by the University of Oxford (UK), has been suspended
  • Hackensack Meridian Health (NJ, USA) observational study demonstrates lack of efficacy of hydroxychloroquine among hospitalized COVID-19 patients, however another drug, tocilizumab, appears to improve survival
  • Chimeron Bio (PA, USA) partners with George Mason University’s National Center for Biodefense and Infectious Diseases (VA, USA) to develop a COVID-19 vaccine using ChaESARTM technology
  • AstraZeneca (Cambridge, UK), the company developing a vaccine in partnership with the University of Oxford (UK) says it may consider exposing trial participants to virus as the disease declines in Europe
  • SAB Biotherapeutics (SD, USA) confirms potency of antibodies to SARS-CoV-2 and begins manufacturing of novel COVID-19 therapeutic candidate SAB-185
  • Ashvattha Therapeutics subsidiary Orpheris (CA, USA) announces FDA approval of Phase II study evaluating OP-101 in severe COVID-19 patients
  • Apellis (MA, USA) initiates Phase I/II study of APL-9 in patients with severe COVID-19
  • Atriva Therapeutics (Tübingen, Germany) is to develop ATR-002 for the treatment of patients with COVID-19 in a Phase II study, following positive preclinical results
  • Cerecor (MD, USA) announces FDA IND clearance for CERC-002 in COVID-19 induced acute respiratory distress syndrome
  • Roche (Basel, Switzerland) initiates Phase III study in partnership with Gilead (CA, USA) to investigate tocilizumab in combination with remdesivir in COVID-19 pneumonia

27 May 2020

  • Anivive (CA, USA) files pre-IND application to FDA for the repurposing of veterinary drug GC376 for COVID-19
  • Montefiore Health System and Albert Einstein College of Medicine (both NY, USA) begin the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), testing remdesivir in combination with baricitinib or placebo
  • Merck & Co. (NJ, USA) CEO Ken Frazier casts doubt on the 12–18-month timeframe to develop an effective vaccine against COVID-19, following the launch of the US government’s “Operation Warp Speed”
  • Ceapro Inc. (Edmonton, Canada) announces collaboration with McMaster University (Hamilton, Canada) to develop inhalable therapeutic for COVID-19
  • WHO expects results from hydroxychloroquine safety review by mid-June, while Algeria continues to administer the drug despite WHO warnings
  • Virna Therapeutics (MA, USA) announces partnership with University of Toronto (Canada) to in-license neutralizing antibodies to treat COVID-19

26 May 2020

  • WHO suspends hydroxychloroquine testing in global COVID-19 trial amid safety fears, while urging Indonesia – a major advocate of the drug – to suspend its use
  • Diffusion Pharmaceuticals (VA, USA) receives accelerated FDA approval to proposed trans sodium crocetinate clinical trial program
  • UK to provide Gilead’s (CA, USA) remdesivir to some COVID-19 patients
  • Merck & Co. (NJ, USA) announces development of two COVID-19 vaccine candidates
  • Glenmark (Mumbai, India) announces another new Phase III clinical trial on a combination of two antiviral drugs, Favipiravir and Umifenovir, as a potential COVID-19 treatment strategy
  • Novavax (MD. USA) initiates Phase I/II trial of COVID-19 vaccine candidate NVX‑CoV2373
  • Algernon (Vancouver, Canada) submits application to the FDA to evaluate ifenprodil as potential treatment for COVID-19

22 May 2020

  • Russian Direct Investment Fund and ChemRar (Moscow, Russia) launch final stage of favipiravir clinical trial
  • CanSino’s (Tianjin, China) COVID-19 recombinant vaccine candidate shows promise in first clinical trial
  • Oxford University (UK) COVID-19 vaccine to begin Phase II/III human trials
  • Atomwise (CA, USA) partners with global research teams to pursue broad-spectrum treatments against COVID-19
  • FibroGenesis (TX, USA) reports significant efficacy for fibroblast cell therapy after pre-clinical trial for COVID-19
  • NovaLead Pharma (NY, USA) to conduct Phase III clinical trials for repurposed drug, NLP21, for COVID-19

21 May 2020

  • AstraZeneca (Cambridge, UK) to receive up to $1.2 billion from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of at least 300 million doses of the University of Oxford’s (UK) COVID-19 vaccine
  • Atossa Therapeutics (WA, USA) announces positive results from in vitro testing of COVID-19 drug candidate AT-H201
  • Vaxart (CA, USA) selects lead COVID-19 vaccine candidate
  • Brazil authorizes the use of hydroxychloroquine to treat COVID-19, with revised guidelines suggesting dosage along with the antibiotic azithromycin at the first onset of symptoms. Patients or family members will have to sign a waiver recognizing the potential side effects caused by the drug
  • Airway Therapeutics (GA, USA) and Celonic Group (Basel, Switzerland) collaborate to produce AT-100 as a therapeutic candidate for COVID-19
  • Progenabiome (CA, USA) commences hydroxychloroquine clinical trials
  • Bharat Biotech (Hyderabad, India) and Thomas Jefferson University (PA, USA) collaborate to develop a promising vaccine candidate against COVID-19
  • Kancera (Solna, Sweden) initiates Phase II trial of anti-hyperinflammation drug KAND567 in COVID-19 patients
  • CanSino Biologics (Tianjin, China) and Precision NanoSystems (Vancouver, Canada) announce collaboration to develop a COVID-19 RNA vaccine
  • IMV (Nova Scotia, Canada) selects a vaccine candidate against COVID-19 to advance into clinical trials
  • First generic version of Gilead’s (CA, USA) remdesivir to be sold by Beximco Pharmaceuticals (Dhaka, Bangladesh)

20 May 2020

  • FDA approves Investigational New Drug (IND) application submitted by Octapharma (Lachen, Switzerland) for a Phase III clinical trial of Octagam for severe COVID-19 patients
  • Hoth Therapeutics (NY, USA) licenses novel peptide therapeutic from Virginia Commonwealth University (USA) for COVID-19
  • Atea Pharmaceuticals (MA, USA) announces IND clearance of AT-527 for COVID-19 and $215 million financing
  • PharmaJet (CO, USA) and Abnova (Taipei, Taiwan) partner to develop a COVID-19 vaccine, to be delivered using needle-free injection technology
  • Adjuvance Technologies (NE, USA) announces NIH funding for COVID-19 vaccine research

19 May 2020

  • Researchers at UT Southwestern (TX, USA) identify three approved drugs that can block the production of SARS-CoV-2
  • Three research laboratories, USAMRIID (MD, USA), Stanford (CA, USA) and UTMB/GNL (TX, USA), confirm that multiple Centivax (CA, USA) antibodies neutralize SARS-CoV-2
  • Covis Pharma (Luxembourg, Switzerland) initiates Phase III clinical trial of Alvesco (ciclesonide) inhaler for the treatment of COVID-19
  • Russia’s acting health minister Mikhail Murashko announces plans to start clinical trials of a vaccine soon
  • Abcore (CA, USA) announces a panel of patent pending functional antibodies for use as therapeutic candidates for the treatment of COVID-19

18 May 2020

  • FDA approves Investigational New Drug (IND) application for the Phase II trial of ViralClear’s (CT, USA) merimepodib in adults with advanced COVID-19
  • Genexine (Seongnam, South Korea) consortium announces their COVID-19 vaccine is ready for human testing
  • Early Phase I data demonstrate Moderna’s (MA, USA) COVID-19 vaccine, mRNA-1273, generates immune responses
  • UK government grants funding for coronavirus vaccine trials at the University of Oxford and Imperial College London (both UK)
  • Blood-thinning drugs could help save COVID-19 patients’ lives, according to specialists at the Royal Brompton Hospital (London, UK)
  • Heath Canada approves the first Canadian clinical trial for a potential COVID-19 vaccine, which is being developed by the Canadian Center for Vaccinology at Dalhousie University (Nova Scotia, Canada)

15 May 2020

  • VSY Biotechnology (Leinfelden-Echterdingen, Germany) announce  a new drug, TR-C 19, is now ready for human testing
  • BioPorto (Hellerup, Denmark) and leading Danish hospitals to test Iloprost as a treatment for critically ill COVID-19 patients
  • NovaLead Pharma (Pune, India) receives clinical trial permission from the Drug Controller General of India for its repurposed drug, NLP21
  • NIH to test hydroxychloroquine and azithromycin combination as a potential COVID-19 treatment
  • Medicago (Quebec city, Canada) announces positive results in animal trials for its COVID-19 vaccine candidate
  • Enzychem Lifesciences (Seoul, South Korea) initiates Phase II study for EC-18 in preventing Acute Respiratory Distress Syndrome (ARDS) due to SARS-CoV-2
  • RESTEM (CA, USA) announces FDA approval for a Phase I/IIa study using umbilical cord mesenchymal stem cells to treat patients with severe cases of COVID-19
  • US study demonstrates convalescent plasma therapy to be safe to treat COVID-19
  • Oxford University (UK) coronavirus vaccine demonstrated to be protective against SARS-CoV-2 in small monkey study

14 May 2020

  • Longeveron (FL, USA) to begin enrolling patients for a clinical trial testing mesenchymal stem cells for moderate to severe ARDS in COVID-19
  • CureVac (Tubingen, Germany) reports preclinical results for its vaccine candidate against SARS-CoV-2, saying a low dose triggers immune response
  • Kaleido Biosciences (MA, USA) initiates controlled clinical study evaluating Microbiome Metabolic Therapy candidate KB109 in outpatients with mild-to-moderate COVID-19
  • Abivax (Paris, France) receives clearance to test its development candidate ABX464 in 1,034 high-risk COVID-19 patients in a randomized Phase IIb/III clinical trial
  • Immunic (NY, USA) receives regulatory approval from German health authority BfArM to initiate a Phase II clinical trial of its DHODH inhibitor, IMU-838, in COVID-19 patients
  • India to test four drugs for COVID-19 as part of the WHO solidarity trial
  • Orgenesis (MD, USA) announces launch of cell-based vaccine platform targeting COVID-19 and other viral diseases
  • Gilead’s (CA, USA) remdesivir is being tested in combination with other drugs to fight COVID-19
  • Pfizer (NY, USA) CEO Albert Bourla announces plans to expand human trials of coronavirus vaccine, BNT162, to thousands of people by September

13 May 2020

  • Veru (FL, USA) receives FDA permission to initiate Phase II study of VERU-111 for the treatment of COVID-19
  • Innovation Medicines Initiative grants €117 million for eight large-scale research projects developing treatments and diagnostics for the coronavirus
  • Gilead signs non-US deals with five generic drugmakers to expand the supply of COVID-19 drug remdesivir
  • NEOVII (Rapperswil, Switzerland) signs agreement with Tel Aviv University (Israel) to develop a novel vaccine for COVID-19
  • YUMAB (Braunschweig, Germany) identifies a promising candidate for COVID-19 antibody therapy
  • The National Research Council of Canada and University of Saskatchewan’s VIDO-InterVac (Canada) collaborate to advance the development of vaccine against COVID-19

12 May 2020

  • NanoViricides (CT, USA) announces the development of broad-spectrum drug candidates against multiple coronaviruses
  • FDA grants fast-track status to Moderna’s (MA, USA) mRNA-1273 vaccine candidate against COVID-19
  • The National Research Council of Canada and CanSino Biologics Inc. (Tianjin, China) announce collaboration to advance vaccine against COVID-19
  • Nascent Biotech (CA, USA) and Manhattan BioSolutions (NY, USA) announce collaboration to advance vaccine discovery and development for COVID-19
  • Glenmark (Maharashtra, India) initiates Phase III clinical trials in India on antiviral Favipiravir for COVID-19
  • Acer Therapeutics (TX, USA) announces plans to develop emetine as a potential COVID-19 treatment, in collaboration with the National Center for Advancing Translational Sciences
  • Bellerophon Therapeutics (NJ, USA) announces FDA clearance for the initiation of a Phase III study for INOpulse inhaled nitric oxide therapy to treat COVID-19
  • EMA recommends expanding remdesivir compassionate use to patients not on mechanical ventilation
  • Themis (Mumbai, India) collaborates with ABL Europe (Strasbourg, France) to manufacture its SARS-CoV-2 vaccine candidate in France

11 May 2020

  • Pfizer (NY, USA) is to outsource more of its drug production to outside contractors in order to focus on large-scale production of an experimental COVID-19 vaccine, should it prove safe and effective
  • the Drug Controller of India allows the initiation of a clinical trial of Favipiravir, developed by the CSIR, on coronavirus patients
  • Indian Council of Medical Research (ICMR) partners with Bharat Biotech International Limited (Hyderabad, India) to develop a COVID-19 vaccine
  • Triple antiviral therapy – interferon-β 1b, lopinavir-ritonavir and ribavirin – shows promise for COVID-19 patients with mild to moderate cases of COVID-19
  • US National Institute of Allergy and Infectious Diseases launches ACTT 2 trial testing Gilead’s (CA, USA) remdesivir plus Eli Lilly (IN, USA) and Incyte’s (DE, USA) Olumiant as a potential treatment for COVID-19

7 May 2020

  • Japan authorizes use of Gilead’s (CA, USA) remdesivir for patients with severe COVID-19
  • Enlivex (Ness Ziona, Israel) announces initiation of investigator-initiated multi-center Phase II clinical trial of Allocetra in COVID-19 patients
  • Moderna (MA, USA) secures FDA approval to advance coronavirus vaccine candidate mRNA-1273 to Phase II testing
  • Tonix Pharmaceuticals (NY, USA) to collaborate with University of Alberta (USA) to develop novel vaccines, TNX-1810, TNX-1820 and TNX-1830, for the prevention of COVID-19
  • Predictive Oncology (MN, USA) announce collaboration with Dr Daniel Carter to develop a potential COVID-19 vaccine utilizing novel nanoparticle vaccine platform based on NSP-10
  • AB Science (Paris, France) announce initiation of Phase II study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19

6 May 2020

  • Relief Therapeutics (Geneva, Switzerland) announces New York University Langone Health’s (USA) participation in the Phase II clinical study of Aviptadil for the treatment of Acute Respiratory Distress Syndrome (ARDS) in COVID-19
  • Tetra Bio-Pharma (Ontario, Canada) announces plans to launch a Phase 1 trial of drug candidate PPP003 in healthy volunteers later this year and subsequent initiation of a Phase II trial in patients with COVID-19 immediately after
  • CSL Behring Australia commences development of COVID-19 Immunoglobulin treatment for serious cases of COVID-19
  • First COVID-19 patient dosed in Humanigen’s (CA, USA) Phase III lenzilumab study
  • Laurent Pharmaceuticals (Montreal, Canada) receives approval from Health Canada to initiate Phase II COVID-19 clinical trial for drug candidate LAU-7b
  • First patients dosed in Phase II/III trial of Mesoblast’s (Melbourne, Australia) remestemcel-l for COVID-19 ARDS
  • Bavarian Nordic enters agreement with AdaptVac (both Copenhagen, Denmark) to license COVID-19 vaccine program
  • Czech institutes announce project to develop COVID-19 vaccine
  • OSE Immunotherapeutics (Nantes, France) announces COVID-19 prophylactic vaccine program
  • Australian BRACE trial of TB vaccine, BCG, for COVID-19 expands to include health workers in Australia, Spain and the Netherlands
  • Adimmune (Taichung City, Taiwan) announce one of their COVID-19 candidate vaccines has been proven effective in animal trials
  • US Public Health Research Institute to study the inhibitory effect of Innovation Pharmaceuticals’ (MA, USA) Brilacidin on SARS-CoV-2 (COVID-19) in primary human immune cells
  • Lineage Cell Therapeutics (CA, USA) to apply allogeneic dendritic cell therapy program to COVID-19 vaccine development

5 May 2020

  • Korean researchers have identified two already FDA-approved drug candidates for COVID-19 treatment – niclosamide and ciclesonide
  • Organicell (FL, USA) announces FDA approval of IND application for Organicell Flow for the treatment of SARS-CoV-2
  • Pfizer (NY, USA) and BioNTech (Mainz, Germany) dose first US participants in global COVID-19 vaccine trial
  • Some COVID-19 patients in Italy report improvement after receiving convalescent plasma therapy
  • University of Pennsylvania (PA, USA) immunologist suggests that even if we succeed in developing an effective vaccine against the coronavirus, it may be less effective for older adults
  • WHO to talk with the US government and Gilead Sciences (CA, USA) on how to make remdesivir more widely available to treat COVID-19

4 May 2020

  • Eli Lilly (IN, USA) and Junshi Biosciences (Shanghai, China) agree to co-develop antibody therapies for the prevention and treatment of COVID-19
  • University Hospital Southampton (UK) trials new coronavirus treatment drug – a special formulation of interferon beta
  • Guy’s and St Thomas’ Hospital (London, UK) to trial blood plasma treatment for COVID-19
  • Alnylam (MA, USA) and Vir (CA, USA) announce plans to advance experimental RNAi therapeutic VIR-2703 as a potential COVID-19 treatment
  • Applied DNA (NY, USA) and Takis Biotech (Rome, Italy) announce that the first injections of their DNA vaccine candidate against SARS-CoV-2 has produced neutralizing antibodies in animals
  • Generex Biotechnology (Toronto, Canada) initiates manufacturing for Ii-Key- SARS-CoV-2 peptide vaccine
  • Arcturus Therapeutics (CA, USA) and Catalent (NJ, USA) announce partnership to manufacture mRNA-based COVID-19 vaccine
  • Anixa Biosciences (CA, USA) and OntoChem (Halle, Germany) announce discovery of first COVID-19 therapeutic candidate

1 May 2020

  • XBiotech (TX, USA) identifies human donors for the development of a True Human™ COVID-19 antibody therapy
  • PROMETRIKA collaborates with Karyopharm Therapeutics (both MA, USA) to conduct the first randomized clinical trial for low-dose selinexor (XPOVIO®) in hospitalized patients with severe COVID-19
  • UH Cleveland opens as the first clinical site for the Phase II/III MACOVIA (MultiStem® Administration for COVID-19 Induced Acute Respiratory Distress Syndrome) study evaluating MultiStem cell therapy for COVID-19-induced ARDS
  • Clinical trial in COVID-19 patients tests IC14, an anti-inflammatory drug developed 25 years ago at Scripps Research CA, USA)
  • Glenmark (Maharashtra, India) receives approval from the DCGI (Drug Controller General of India) to conduct clinical trials testing Favipiravir Antiviral tablets in COVID-19 patients
  • EMA commences rolling review of remdesivir for the treatment of COVID-19

30 April 2020

  • Eiger BioPharmaceuticals (CA, USA) announces first COVID-19 patients dosed with peginterferon lambda at Stanford University School of Medicine (CA. USA)
  • Vaxart (CA, USA) announces positive pre-Clinical results for its oral COVID-19 vaccine candidates
  • AstraZeneca (Cambridge, UK) enters deal to manufacture University of Oxford’s (UK) potential COVID-19 vaccine
  • BeiGene (Beijing, China), Atreca and IGM Biosciences (both CA, USA) collaborate to develop novel antibody treatment for COVID-19
  • Algernon (Vancouver, Canada) receives clearance for NP-120 (Ifenprodil) COVID-19 Phase IIb/III  clinical trial
  • Clinical trial launched in New York to test convalescent plasma for the treatment of COVID-19
  • Verndari Inc. (CA, USA) commences preclinical testing of COVID-19 vaccine at University of California
  • University of Queensland’s (Australia) COVID-19 vaccine shown to induce protective immune response in pre-clinical trials
  • IIT Guwahati (India) collaborates with Hester Biosciences (Ahmedabad, India) to develop COVID-19 vaccine
  • Capricor (CA, USA) reports 100% Survival in six critical COVID-19 patients treated with CAP-1002
  • CytoDyn (WA, USA) reports positive results from emergency IND use in COVID-19 patients treated with leronlimab

29 April 2020

  • Secarna Pharmaceuticals (Munich, Germany) collaborates with Sun Yat-sen University (Guangzhou, China) to develop a treatment for SARS-CoV-2
  • Pfizer’s (NY, USA) coronavirus vaccine could be ready for use on an emergency basis in the fall
  • Formycon (Munich, Germany) initiates antibody-based drug development for COVID-19
  • Chimerix (NC, USA) initiates Phase II/III study of DSTAT in acute lung injury for patients with severe COVID-19
  • Gilead (CA, USA) reports remdesivir study in hospitalised COVID-19 patients met the primary endpoint
  • BerGenBio’s (Bergen, Norway) bemcentinib selected to be fast-tracked for a Phase II clinical trial as a potential treatment for COVID-19 through new national UK government clinical trial initiative
  • BioNTech (Mainz, Germany) and Pfizer (NY, USA) finish dosing first cohort of Phase I/II trial of COVID-19 vaccine candidates
  • Vicore Pharma (Gothernburg, Sweden) garners approval to initiate Phase II clinical trial with VP01 (C21) in patients with COVID-19
  • All India Institute of Medical Sciences announces plans to conduct clinical trial of plasma therapy for COVID-19 patients
  • India’s Serum Institute (Pune) announces plans to produce up to 60 million doses of Oxford’s (UK) vaccine candidate, ChAdOx1 nCoV-19
  • R-Pharm (Moscow, Russia) and Cromos Pharma (OR, USA) announce initiation of randomized clinical trial evaluating Olokizumab and RPH-104 in patients with severe COVID-19
  • INOVIO (PA, USA) completes enrollment in the Phase I trial of INO-4800 for COVID-19 DNA vaccine, with interim results expected in June

28 April 2020

  • Faron Pharmaceuticals (Helsinki, Finland) announces plans to donate supplies of its investigational intravenous interferon (IFN) beta-1a for 2,000 patients in the WHO’s Solidarity trial investigating potential COVID-19 treatments
  • CEPI (Oslo, Norway) announces partnership with Clover Biopharmaceuticals’ (Chengdu, China) Australian subsidiary to develop COVID-19 vaccines
  • Tetra Bio-Pharma (Ontario, Canada) announces drug candidate, PPP003, as potential therapy for managing cytokine release syndrome in COVID-19
  • Japan to approve Gilead’s (CA, USA) remdesivir for coronavirus patients in May
  • Pneumagen (St Andrews, Scotland) announces positive anti-viral activity for novel glycan approach in preventing COVID-19 infections
  • Shionogi (NJ, USA) initiates collaborative research effort to develop potential COVID-19 treatments and vaccine
  • PharmaMar (Madrid, Spain) announces Authorization of the APLICOV-PC clinical trial With Aplidin (plitidepsin) for the treatment of patients with COVID-19
  • Moderna (MA, USA) announces IND submission to FDA for Phase II study of mRNA vaccine (mRNA-1273) against COVID-19

27 April 2020

  • Sinopharm’s (Beijing, China) inactivated COVID-19 vaccine enters Phase II clinical trial
  • ARTES Biotechnology (Langenfeld, Germany) enters development of SARS-CoV-2 vaccine candidates using its virus-like particle-based platform technologies
  • Mateon (CA, USA) submits IND application to FDA to evaluate its investigational drug, OT-101, for the treatment of COVID-19
  • Kamada (Rehovot, Israel) and Kedrion Biopharma (Barga, Italy) announce collaboration for the development, manufacturing and distribution of a plasma-derived anti-SARS-CoV-2 polyclonal immunoglobulin product
  • Six COVID-19 patients treated with RedHill’s (Tel-Aviv, Israel) opaganib under compassionate use show clinical improvement
  • TriLink BioTechnologies (CA, USA) and Imperial College London (UK) announce collaboration to produce saRNA for COVID-19 vaccine development
  • Romark (FL, USA) initiates two Phase III clinical trials of investigational new drug candidate NT-300 for COVID-19

24 April 2020

  • Promising results in study of COVID-19 patients with moderate/severe Acute Respiratory Distress Syndrome treated with Mesoblast’s (Melbourne, Australia) cell therapy, pemestemcel-L
  • BioSig Subsidiary ViralClear (CT, USA) submits Investigational New Drug Application to the FDA for Phase II Cclinical trials for Merimepodib as a treatment for COVID-19
  • FDA grants approval for Columbia University Mailman School of Public Health (NY, USA) to launch clinical trials to determine whether blood plasma from COVID-19 survivors can be used to prevent infections in high-risk individuals
  • Scancell (Oxford, UK) to initiate development of novel DNA vaccine against COVID-19
  • AdaptVac (Copenhagen, Denmark) partners with AGC Biologics (WA, USA) to develop a COVID-19 vaccine
  • Oryzon (Barcelona, Spain) to initiate ESCAPE: a Phase II clinical trial to test the efficacy of vafidemstat in severely ill COVID-19 patients
  • hVIVO (London, UK) commences the testing of an anti-viral for treating COVID-19 on behalf of its client Nearmedic (Moscow, Russia)

23 April 2020

  • First patients injected in Oxford (UK) vaccine trial
  • Algernon (Vancouver, Canada) announces approval for Phase II clinical study of its repurposed drug NP-120 (Ifenprodil) for COVID-19
  • Brensocatib (Formerly INS1007) to be tested in patients with severe COVID-19 in investigator-initiated trial
  • ReiThera (Rome, Italy), Leukocare (Munich, Germany) and Univercells (Charleroi, Belgium) announce strategic collaboration for the development of a single-dose adenovirus-based COVID-19 vaccine
  • AstraZeneca (Cambridge, UK) and Saint Luke’s Mid America Heart Institute IMO, USA) initiate Phase III DARE-19 trial treating COVID-19 patients with Farxiga (dapagliflozin)
  • Valneva (Nantes, France) and Dynavax (CA, USA) announce collaboration to advance vaccine development for COVID-19
  • Hemogenyx Pharmaceuticals PLC (London, UK) initiates COVID-19 project to develop novel therapies

22 April 2020

  • Q BioMed (NY, USA) and Mannin (Toronto, Canada) initiate rapid development of novel COVID-19 therapeutics
  • Pharnext (Paris, France) and the University Hospital Institute Méditerranée Infection (Marseille, France) announce a joint effort to evaluate repurposed drugs for potential use against COVID-19
  • Algernon Pharmaceuticals (Vancouver, Canada) submits application to Health Canada for ifenprodil COVID-19 Phase IIb/III multinational clinical trial
  • Pfizer (NY, USA) and BioNTech (Mainz, Germany) announce approval of a Phase I/II trial of the BNT162 vaccine programme to prevent COVID-19 infection
  • Viravaxx AG (Vienna, Austria) announces the launch of a project for combating COVID-19 together with the Medical University of Vienna
  • Oncology Venture (Copenhagen, Denmark) to test activity of its PARP inhibitor, 2X-121, as a potential therapy for coronavirus
  • Immunic Therapeutics (NY, USA) reports that IMU-838 has demonstrated preclinical activity against SARS-CoV-2
  • SOM Biotech (Barcelona, Spain) to test three drug candidates for COVID-19 in vitro, in collaboration with the Ewha Womans University (Seoul, South Korea)
  • Sepsivac, a sepsis drug jointly developed by Cadilla Pharmaceuticals (Ahmedabad, India) and the Council for Scientific and Industrial Research (CSIR; Pretoria, South Africa), will be tested in 50 COVID-19 patients at the All-India Institute of Medical Sciences

21 April 2020

  • Microsoft (WA, USA) launches self-screening tool “Plasma Bot” to gather plasma donations from recovered COVID-19 patients for potential antibody-based therapy, while Grifols (Barcelona, Spain) announces it has begun screening and selecting volunteer donors who have recovered from COVID-19 to donate their plasma in select US cities
  • aTyr Pharma  (CA, USA) announces Phase II study of ATYR1923 in COVID-19 patients with severe respiratory complications following FDA acceptance of IND application
  • Bayer (Leverkusen, Germany) partners with Population Health Research Institute (PHRI; Hamilton, Canada) on major global research study with the aim of identifying potential COVID-19 treatments. The two studies will evaluate different combination therapies including Bayer’s chloroquine and interferon beta-1b
  • Hope Biosciences (TX, USA) announces third FDA-approved clinical trial for COVID-19 treatment
  • COVID-19 drug trial, ASCOT, under way in Australia to test the malaria drug hydroxychloroquine and the HIV treatment lopinavir/ritonavir on patients infected with the novel coronavirus
  • Pharming Group (Leiden, Netherlands) reports encouraging results from use of RUCONEST in five COVID-19 patients under a compassionate use program at the University Hospital Basel (Switzerland)
  • Vivacelle Bio (IL, USA) announces compassionate use for COVID-19 patients with its sepsis treatment, VBI-S, after encouraging preliminary results
  • Takara Bio (Kusatsu, Japan) announces plans to to mass-produce COVID-19 vaccine candidate
  • Edesa Biotech (Markham, Canada) and Light Chain Bioscience (Geneva, Switzerland) collaborate to develop and commercialize two Phase II-ready biologic drug candidates for COVID-19 pneumonia and other disorders
  • Alexion (MA, USA) announces plans to investigate effects of C5 inhibition with Ultomiris (ravulizumab-cwvz) in hospitalized patients with severe COVID-19
  • Following the screening of 11,552 compounds, Innovation Pharmaceuticals (MA, USA) reports their drug Brilacidin to be one of the most promising potential inhibitors of COVID-19

20 April 2020

  • RedHill Biopharma (Tel Aviv, Israel) announces agreement with National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to evaluate its investigational drug, RHB-107, against COVID-19 in pre-clinical testing
  • NanoPass (Ness Ziona, Israel) is to join forces with leading vaccine and immunotherapy companies around the world to develop a COVID-19 vaccine, and is sharing its proprietary MicronJet microneedle device
  • Anixa Biosciences (CA, USA) and OntoChem (Halle, Germany) announce strategic collaboration to develop novel COVID-19 therapeutics
  • Alexion (MA, USA) announces plans to initiate Phase III study of Ultomiris (ravulizumab-cwvz) in hospitalized patients with severe COVID-19
  • 4D Pharma (Leeds, UK) announces acceptance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence a Phase II study of MRx-4DP0004 in patients with COVID-19
  • Zydus Cadila (Ahmedabad, India) announces that its biological therapy Pegylated Interferon alpha-2b (PegiHepTM) has potential for the treatment of COVID 19
  • Novartis (Basel, Switzerland) to conduct Phase III study of hydroxychloroquine for hospitalized patients with COVID-19
  • India’s central drug regulator approves proposal by the Indian Council of Medical Research (ICMR) for the clinical trial of convalescent plasma in COVID-19 patients

17 April 2020

  • World’s biggest trial of treatments for COVID-19 begins in Oxford (UK)
  • China cancels approximately 40 COVID-19-related clinical trials as epidemic ebbs
  • Karolinska Development’s (Stockholm, Sweden) portfolio company Dilafor initiates collaboration with Liverpool University for preclinical study of tafoxiparin on SARS-CoV-2
  • Early data from Phase III studies suggest Gilead’s (CA, USA) remdesivir leads to rapid recoveries in fever and respiratory symptoms in COVID-19 patients
  • Mayo Clinic (NY, USA) prepares to commence Phase II FDA clinical trial for the treatment of COVID-19 with Vicromax (merimepodib)
  • Selinexor (XPOVIO®), a drug studied at Karmanos Cancer Institute (MI, USA) enters clinical trials for treatment of COVID-19
  • Sinovac (Beijing, China) announces commencement of Phase I human clinical trial for vaccine candidate against COVID-19

16 April 2020

  • Vanda Pharmaceuticals (WA, USA) and Northwell Health (NY, USA) enroll first patient in ODYSSEY trial investigating the efficacy and safety of tradipitant in severe COVID-19 pneumonia
  • Bold Therapeutics (Vancouver, Canada) and the University of Ottawa (Canada) announce initiation of Research partnership to explore the potential utility of BOLD-100 as a novel antiviral agent for the treatment of COVID-19
  • Roivant (Basel, Switzerland) doses first patient in BREATHE clinical trial evaluating gimsilumab in COVID-19 patients for the prevention and treatment of Acute Respiratory Distress Syndrome
  • FDA Approves initiation of Humanigen’s (CA, USA) Phase III study of lenzilumab in COVID-19 patients
  • Swissmedic approves first COVID-19 therapy study with convalescent plasma, which will take place at the University Hospital of Zurich (Switzerland)
  • Eagle Pharmaceuticals (NJ, USA) announces laboratory test results demonstrating in vitro antiviral activity of RYANODEX (dantrolene sodium) against coronavirus SARS-CoV-2
  • Starpharma (Victoria, Australia) announces positive results for SPL7013 against SARS-CoV-2
  • Oxford University (UK) to begin human trials of COVID-19 vaccine next week
  • IVI (Seoul, South Korea), Inovio (PA, USA) and KNIH to Partner with CEPI (Oslo, Norway) in Phase I/II clinical trial of Inovio’s COVID-19 DNA vaccine
  • Dynavax (CA, USA) and Sinovac (Beijing, China) announce collaboration to develop a COVID-19 vaccine using Dynavax’s CpG 1018 and Sinovac’s chemically inactivated vaccine candidate
  • Biogen, Broad Institute of MIT and Harvard, and Partners HealthCare (all MA, USA) launch consortium to build and share a COVID-19 biobank
  • Atossa Therapeutics (WA, USA) launches COVID-19 HOPE drug development program
  • PDS Biotechnology (NJ, USA) initiates novel vaccine development program for COVID-19
  • FDA encourages recovered patients to donate plasma for development of blood-related therapies
  • University of Edinburgh (UK) researchers re-deployed to work on a new project termed STOPCOVID testing existing and experimental drugs for the treatment of COVID-19

15 April 2020

  • Ensysce Biosciences (CA, USA) announces plans to explore the initiation of a clinical trial of oral Nafamostat as a treatment for COVID-19
  • Nucleus Network (Melbourne, Australia) is due to commence clinical Phase 1 testing for the Novavax SARS-CoV-2 Recombinant Spike Protein Nanoparticle vaccine, NVX-CoV2373, within the coming weeks
  • 7 Hills Pharma (TX, USA) announces coronavirus vaccine program targeting at-risk elderly, while searching for collaborators
  • Flow Pharma (CA, USA) announces strategic partnership with Oakwood Labs (OH, USA) for GMP manufacturing of FlowVax COVID-19 vaccine
  • HALIX (Leiden, Netherlands) enters collaboration with the University of Oxford (UK) for GMP manufacturing of a COVID-19 vaccine, ChAdOx1 nCoV-19
  • Ansun Biopharma (CA, USA) enrolls first patient in proof of concept trial of DAS181 for the treatment of COVID-19
  • First patient treated with leronlimab, a potential COVID-19 therapy, in Phase IIb/III trial
  • Khondrion (Nijmegen, Netherlands) highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 and proposes that its lead drug candidate, sonlicromanol, could be repurposed for the treatment of patients with severe COVID-19

14 April 2020

  • Ligandal (CA, USA) announces plans to develop a potential antidote and vaccine for SARS-CoV-2 using peptide scaffolds
  • UNION therapeutics (Copenhagen, Denmark) launches program in collaboration with Institut Pasteur Korea to test an optimized salt form of niclosamide as a treatment for COVID-19
  • Cansino Biologics (Tianjin, China) begins recruiting participants for a Phase II clinical trial of its coronavirus vaccine candidate Ad5-nCoV
  • AstraZeneca (Cambridge, UK) announces plans to investigate the potential of the BTK inhibitor Calquence (acalabrutinib) in the treatment of cytokine storm associated with COVID-19 infection in severely ill patients
  • Afecta Pharmaceuticals (CA, USA) to submit two of its lead COVID-19 drug candidates to the National Institute of Health (MD, USA) to be evaluated for initiation of pre-clinical and potential clinical testing
  • NantKwest and ImmunityBio (both CA, USA) collaborate to develop therapeutics and vaccines against COVID-19, with clinical trials anticipated to begin this quarter
  • KD Pharma Group (Bioggio, Switzerland) and SLA Pharma (Liestal, Switzerland) initiate clinical trial of their new drug candidate EPAspire™ for COVID-19
  • GlaxoSmithKline (London, UK) and Sanofi (Paris, France) team up to develop adjuvanted vaccine against COVID-19

9 April 2020

  • CSL Behring (PA, USA) and SAB Biotherapeutics (MA, USA) in partnership to deliver a new potential COVID-19 therapeutic
  • Vancouver Infectious Diseases Centre joins Montreal Heart Institute (both Canada) to evaluate the use of colchicine as a potential treatment against COVID-19
  • FDA approves trial testing Fujifilm’s influenza drug Avigan against the coronavirus
  • Axon Neuroscience (Slovakia) announces development of a promising vaccine candidate against COVID-19
  • FirstWave Bio (MI, USA) to initiate Phase IIa/IIn study of FW-1022, a proprietary form of niclosamide, to treat COVID-19

8 April 2020

  • Viriom (CA, USA) initiates Phase II clinical trial of elsulfavirine for treatment of moderate COVID-19
  • MediciNova (CA, USA) announces plans to initiate a clinical trial of MN-166 (ibudilast) for COVID-19 acute respiratory distress syndrome
  • Flow Pharma (CA, USA) announces initiation of pre-clinical study to test efficacy of FlowVax COVID-19 vaccine
  • Chugai (Tokyo, Japan) starts Phase III clinical trial of monoclonal antibody treatment Actemra for COVID-19 pneumonia
  • Oxford Biomedica (UK) joins Consortium to rapidly develop a COVID-19 vaccine candidate, ChAdOx1 nCov-19
  • Novant Health (NC, USA) starts Phase II COVID-19 trial testing CytoDyn’s (WA, USA) leronlimab
  • Oral antiviral EIDD-2801 shows promising preclinical results against COVID-19
  • FDA approves Investigational New Drug application, allowing Ridgeback Biotherapeutics (FL, USA) to begin human testing of EIDD-2801, a potential treatment for COVID-19
  • Serum Institute of India (Pune, India) currently testing two COVID-19 vaccine candidates in preclinical trials
  • Kedrion Biopharma (Lucca, Italy) announces initiation of the development of a plasma-based therapy for treating COVID-19
  • The Vector Institute (Kol’tsovo, Russia) announces plans to start clinical trials for coronavirus in June
  • Queen’s University (Belfast, UK) leading cell therapy clinical trial to help improve outcomes in COVID-19 patients
  • The Montreal Heart Institute (Canada) announces partnership with the NYU Grossman School of Medicine (NY, USA) for its COVID-19 clinical study evaluating colchicine for preventing major inflammatory storm
  • Cytovia Therapeutics (NY, USA) and Macromoltek (TX, USA) to develop natural killer immunotherapy against SARS-CoV-2
  • Mateon (CA, USA) expands its COVID-19 therapeutic program to include anti-malarial drug Artemisinin

7 April 2020

  • Imophoron (Bristol, UK) uses new vaccine platform, the ADDomer©, to develop COVID-19 candidates
  • The first patients enrol in a trial testing the Roche’s (Basel, Switzerland) arthritis drug Actemra against the coronavirus
  • First published clinical trial for treatment of COVID-19 using lopinavir and ritonavir deemed successful by Lancaster University (UK) academic
  • Plans for controlled distribution of hydroxychloroquine, chloroquine and Kaletra (lopinavir & ritonavir) in Belgium have been announced to enhance monitoring of treatments
  • MedinCell (France) launches a COVID-19 research initiative to formulate long-acting injectable Ivermectin after positive preclinical results from Monash University (Melbourne, Australia)
  • Global plasma leaders collaborate to accelerate development of potential COVID-19 hyperimmune therapy
  • Applied Biology (CA, USA) to launch COVID-19 drug discovery platform for based on discovery made in collaboration with Brown University (RI, USA) researchers
  • Healx (Cambridge, UK) announces use of artificial intelligence to find combination drug treatments for COVID-19, with combination therapy candidates expected in May

6 April 2020

  • Inovio (PA, USA) to begin dosing in Phase I clinical trial of INO-4800 DNA vaccine candidate for COVID-19
  • RedHill Biopharma (Israel) announces first COVID-19 patient treated with investigational new drug opaganib in Israel under compassionate use
  • Izana Bioscience (Oxford, UK) initiates study involving namilumab in the treatment of individual patients with rapidly worsening COVID-19 infection in Italy
  • OncoSec (NJ, USA) and Providence Cancer Institute (OR, USA) to conduct first-in-human trial of OncoSec’s CORVax12, an investigational vaccine to prevent COVID-19
  • First two patients enrolled in randomized Phase II trial testing leronlimab for treatment of COVID-19
  • FDA clears investigational new drug application for Mesoblast (Melbourne, Australia) to use remestemcel-L for treating COVID-19 patients with acute respiratory distress

3 April 2020

  • Trial drug against COVID-19 shows promise in engineered human tissues
  • COVID-19 vaccine candidate shows promise in preclinical research
  • Ennaid Therapeutics (GA, USA) announces development of ENU200, a novel antiviral therapeutic, for the treatment of COVID-19
  • University Hospital Basel (Switzerland) transfuses first two COVID-19 patients With INTERCEPT-treated coronavirus convalescent plasma
  • PharmaMar (Madrid, Spain) submits a Phase II clinical trial protocol of plitidepsin for the treatment of COVID-19 to the Spanish Medicines Agency
  • Vanda Pharmaceuticals (WA, USA) announces the initiation of ODYSSEY, an FDA-approved Phase III clinical study of tradipitant in hospitalized patients with Severe COVID-19 pneumonia
  • Incyte (DE, USA) and Novartis (Basel, Switzerland) to initiate a Phase III study testing ruxolitinib for severe COVID-19 patients
  • Flinders University (Adelaide, Australia) begins testing of COVID-19 vaccine candidate
  • Celltrion’s (Incheon, South Korea) COVID-19 antiviral treatment enters the second phase of development
  • Anti-parasitic drug ivermectin kills COVID-19 in Monash Biomedicine Discovery Institute (Vicotria, Australia) lab
  • I-Mab (China) announces FDA clearance of Investigational New Drug application (IND) to initiate clinical study for TJM2 to treat cytokine release syndrome (CRS) associated with COVID-19

2 April 2020

  • Noxopharm (New South Wales, Australia) to investigate potential for idronoxil in treating COVID-19
  • Algernon (Vancouver, Canada) announces plans to initiate Phase II clinical testing of ifenprodil for COVID-19 among patients in South Korea
  • Applied Therapeutics (NY, USA) announces Investigational New Drug clearance with FDA and investigator-initiated studies of AT-001 to address acute lung inflammation and cardiomyopathy in critical COVID-19 patients
  • Ansun Biopharma (CA, USA) announces positive results from investigator-initiated trial of DAS181, a novel COVID-19 treatment
  • Celularity (NJ, USA) announces FDA clearance of Investigational New Drug application for CYNK-001 in treating the coronavirus, and plans to commence a Phase I/II clinical study
  • Amgen (CA, USA) and Adaptive Biotechnologies (WA, USA) collaborate to develop neutralising antibodies targeting SARS-CoV-2
  • APEIRON Biologics (Vienna, Austria) initiates Phase II clinical trial of APN01 for treatment of COVID-19
  • Malaria drug hydroxychloroquine helps to speed the recovery of patients in a small study conducted at the Renmin Hospital (Wuhan, China)

1 April 2020

  • Gilead (CA, USA) set to begin two Phase III randomised studies testing the safety and antiviral activity of remdesivir in participants with moderate to severe COVID-19
  • Innovation Pharmaceuticals (MA, USA) receives data supporting brilacidin’s direct inhibition of SARS-CoV-2 in preclinical testing
  • FDA launches programme, dubbed the Coronavirus Treatment Acceleration Programme, to speed development of COVID-19 treatments
  • Fujifilm Pharmaceuticals (MA, USA) initiates clinical trials to assess the effectiveness of its influenza drug Avigan treat the coronavirus
  • Ostrich Pharma USA (MA, USA) develops antibodies to block the SARS-CoV-2
  • Neurimmune (Zurich, Switzerland) and Ethris (Munich, Germany) collaborate to develop inhaled mRNA-based antibody therapy for the treatment of COVID-19
  • InflaRx (Jena, Germany) treats the first patient in a multicenter randomized controlled clinical trial with IFX-1 in patients with severe COVID-19 pneumonia in the Netherlands
  • Synairgen (Southampton, UK) confirms commencement of dosing in trial of SNG001 for patients with COVID-19

31 March 2020

  • Israel Institute for Biological Research initiates testing of a COVID-19 vaccine prototype on animal models at its bio-chemical defence laboratory
  • VBI Vaccines (MA, USA) announces collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS
  • Senhwa Biosciences’ (Taiwan) drug silmitasertib reported as potential COVID-19 therapy, according to recent research from the University of California San Francisco (CA, USA)
  • GigaGen (CA, USA) initiates development of recombinant polyclonal antibody therapy, recombinant anti-coronavirus 19 hyperimmune gammaglobulin, for treatment of COVID-19
  • Cobra Biologics (Keele, UK) and the Karolinska Institutet (Sweden) collaborate to develop COVID-19 vaccine

27 March 2020

  • iBio (DE, USA) announces advancement of COVID-19 vaccine program, IBIO-200
  • Sanofi (France) and Translate Bio (MA, USA) to jointly develop mRNA vaccine for COVID-19
  • Altasciences (Canada) completes Phase I study on gimsilumab for acute respiratory distress syndrome in COVID-19
  • Vyripharm Biopharmaceuticals (TX, USA) announces plans to repurpose the development of a novel theranostic platform for the diagnosis, monitoring and treatment of viral infections such as COVID-19.
  • ImmuneMed (Korea) to test its potential COVID-19 cure, HzVSF, outside Korea, after efficacy was demonstrated in five hospitalized patients
  • BioDuro LLC (CA, USA)  announces the initiation of a COVID-19 nanobody therapeutic program
  • New York state Health Department officials report plans to begin clinical trials next week for a malaria drug combination (hydroxychloroquine, Zithromax and chloroquine) that appears to hold some promise for battling COVID-19

26 March 2020

  • NeuroClear (CT, USA) acquires license to develop a broad-spectrum anti-viral agent that could treat COVID-19, with initial laboratory results demonstrating a high level of activity against COVID-19
  • Sorrento (CA, USA) launches novel STI-6991 I-Cell COVID-19 cellular vaccine program
  • Xencor and Vir Biotechnology (both CA, USA) enter license agreement for use of Xtend XmAb antibody technology for investigating antibodies as potential treatments for patients with COVID-19
  • Murdoch Children’s Research Institute (Australia) to trial BCG vaccine against COVID-19
  • Relief Therapeutics (Switzerland) and NeuroRx Inc (DE, USA) file an Investigational New Drug application with the US FDA for a phase II trial of RLF-100 (Aviptadil) in the treatment of COVID-19-induced Acute and Moderate Respiratory Distress

25 March 2020

  • Researchers at Duke-NUS Medical School (Singapore) plan to start testing a COVID-19 vaccine candidate later this year
  • Mateon (CA, USA) reports positive results for multiple COVID-19 drug candidates
  • Vir Biotechnology (CA, USA) to proceed with two clinical development candidates for COVID-19 after announcing that it has identified multiple human monoclonal antibody development candidates that neutralize SARS-CoV-2
  • Clinical study from Ascletis Pharma (China) using danoprevir with ritonavir to treat naive and experienced COVID-19 patients has yielded promising results

24 March 2020

FDA approves Phase III trial of Actemra, developed by Roche (Swizerland), for hospitalised patients with severe COVID-19 pneumonia

23 March 2020

  • Bayer (Germany), Novartis (Switzerland) and Teva (Israel) donate chloroquine and hydroxychloroquine in hopes antimalarials are effective against COVID-19
  • UK clinical testing on an Oxford University (UK) COVID-19 vaccine candidate dubbed ChAdOx1 could begin as early as next month

20 March 2020

  • Roche (Basel, Switzerland) announce they have initiated a Phase III study to investigate the use of Actemra/RoActemra (tocilizumab) plus standard-of-care in hospitalised adults with severe COVID-19 pneumonia compared to placebo plus standard of care
  • Study results published in the New England Journal Of Medicine suggest that the addition of AbbVie’s (IL, USA) Kaletra (lopinavir/ritonavir) to standard care in seriously ill patients with confirmed COVID-19 did not significantly shorten the time to clinical improvement and also not significantly lower mortality rates, compared to standard care alone

18 March 2020

In trials conducted on 200 patients in Wuhan and Shenzhen, Fujifilm’s (Tokyo, Japan) Avigan was shown to reduce pneumonia symptoms, while subjects who received the drug tested negative for the SARS-CoV-2 virus in a shorter time

17 March 2020

16 March 2020

  • Sanofi (Paris, France) and Regeneron Pharmaceuticals (NY, USA)  announce that they have initiated a clinical programme evaluating whether IL-6 inhibition with Kevzara (sarilumab) is better than current supportive care alone for patients hospitalized with severe COVID-19. A Phase II/III study wll be carried out in the USA, led by Regeneron, and will begin enrolling patients immediately
  • BioNTech (Germany) and Fosun Pharmaceutical (China) announce a strategic collaboration to advance BioNTech’s mRNA vaccine candidate BNT162 in China for the prevention of COVID-19 infections
  • CureVac (Tübingen, Germany) said that it “rejects allegations about offers for acquisition of the company or its technology” following reports that US President Donald Trump has sought exclusive access to the German drugmaker’s work on an mRNA-based vaccine against COVID-19

10 March 2020

The Bill & Melinda Gates Foundation (WA, USA) state that it has launched a $125-million seed fund, along with partners Wellcome (London, UK) and Mastercard (NY, USA), to help find potential treatments for COVID-19.

6 March 2020

  • Analysts at RBC Capital Marketing give Gilead’s (CA, USA) remdesivir 50% chance of success as COVID-19 treatment
  • The Coalition for Epidemic Preparedness Innovations (CEPI) put out a call on Friday for $2 billion in new funding to support the development of a vaccine for COVID-19

4 March 2020

  • Takeda (Tokyo, Japan) starts work on TAK-888, an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG), to treat high-risk individuals with COVID-19
  • Arcturus Therapeutics (CA, USA) announces it’s collaboration with Duke-NUS Medical School (Singapore) to develop a COVID-19 vaccine based on the company’s STARR Technology, which could produce a vaccine response at much lower doses than traditional mRNA vaccines
  • Alnylam Pharmaceuticals (MA, USA) and Vir Biotechnology (CA, USA) announces their plan to expand their existing collaboration to include the development and commercialisation of RNAi therapeutics targeting SARS-CoV-2

Leave A Comment